Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal Phase III trial with firibastat in resistant hypertension

Trial Profile

A pivotal Phase III trial with firibastat in resistant hypertension

Planning
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Firibastat (Primary)
  • Indications Resistant hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Quantum Genomics
  • Most Recent Events

    • 17 Jan 2019 According to a Quantum Genomics media release, the steering committee includes Keith C. Ferdinand, William B. White and Jacques Blacher.
    • 17 Jan 2019 According to a Quantum Genomics media release, the company is preparing to launch this trial, thus paving the way for marketing authorisation.
    • 17 Jan 2019 According to a Quantum Genomics media release, the company has announced the appointment of the steering committee for this pivotal trial.The steering committee will work closely with Quantum Genomics scientific team to define the design of this trial, in particular its methodology, target population and evaluation criteria, and will be involved in discussions with the EMA and FDA.It will also be directly involved in this trials conduct.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top